Eylea HD Side Effects

Generic name: aflibercept ophthalmic

Medically reviewed by Drugs.com. Last updated on Sep 9, 2023.

Note: This document contains side effect information about aflibercept ophthalmic. Some dosage forms listed on this page may not apply to the brand name Eylea HD.

Applies to aflibercept ophthalmic: intraocular solution.

Serious side effects of Eylea HD

Along with its needed effects, aflibercept ophthalmic (the active ingredient contained in Eylea HD) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking aflibercept ophthalmic:

More common

Blindness
bloody eye
blurred vision
eye or eyelid redness
eye pain
seeing flashes, sparks of light, or a veil or curtain
seeing floating spots before the eyes
vision changes

Less common

Bleeding or pain at the injection site
swelling of the eyelid

Rare

Chest tightness
fast heartbeat
fever
headache
hives, itching, rash, or skin redness
hoarseness
irritation
joint pain, stiffness, or swelling
swelling of the eye, face, lips, hands, or feet
trouble breathing or swallowing

Incidence not known

Pain in the chest, groin, or legs, especially the calves
severe, sudden headache
slurred speech
sudden loss of coordination
sudden, severe weakness or numbness in the arm or leg

Other side effects of Eylea HD

Some side effects of aflibercept ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Feeling like something is in the eye
watery eyes

For Healthcare Professionals

Applies to aflibercept ophthalmic: intravitreal solution.

General

The more commonly reported adverse reactions have included conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.^[Ref]

Ocular

Very common (10% or more): Conjunctival hemorrhage (28%), eye pain (13%),

Common (1% to 10%): Cataract, vitreous floaters, corneal erosion, intraocular pressure increased, conjunctival hyperemia, ocular hyperemia, vitreous detachment, foreign body sensation in eyes, lacrimation increased, vision blurred, intraocular inflammation, retinal pigment epithelium tear, injection site hemorrhage, eyelid edema, corneal edema, retinal degeneration, cataract, cataract nuclear, cataract subcapsular, corneal abrasion, intraocular pressure increased, vitreous floaters

Uncommon (0.1% to 1%): Retinal detachment, retinal tear, endophthalmitis injection site pain, traumatic cataract^[Ref]

Local

Common (1% to 10%): Injection site pain^[Ref]

Cardiovascular

Intravitreal use of VEGF inhibitors has been associated with a potential risk of arterial thromboembolic events (ATEs) defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including death of unknown cause). In wet age-related macular degeneration (AMD) studies, 1.8% (n=32/1824) and 1.5% (n=9/595) of patients treated with this drug or ranibizumab, respectively, experienced an ATE in the first 52 weeks and 3.3% and 3.2% through 96 weeks, respectively. In the diabetic macular edema (DME) studies, ATEs were reported at incidences of 3.3% (n=19/578) and 2.8% (n=8/287) through week 52, and 6.4% (n=37/578) and 4.2% (n=12/287) through week 100, in patients receiving 2 different dosing regimens of this drug or macular laser photocoagulation (after the first 24 weeks, all patients could receive drug or laser treatment). No ATEs have been reported in the first 6 months of the retinal vein occlusion (RVO) studies.^[Ref]

Common (1% to 10%): Arterial thromboembolic events^[Ref]